OF
KRYS icon

Optimize Financial’s Krystal Biotech KRYS Stock Holding History

Optimize Financial’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$442K Sell
1,710
-1,145
-40% -$305K 0.22% 155
2025
Q4 		$704K Buy
2,855
+40
+1% +$8.42K 0.35% 67
2025
Q3 		$497K Buy
+2,815
New +$421K 0.26% 113

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Optimize Financial's KRYS Position: Q1 2026 in Review

Optimize Financial reduced its Krystal Biotech (KRYS) stake by 40% in Q1 2026, selling an estimated $305K and leaving 1,710 shares worth $442K. The position accounts for 0.22% of the portfolio, ranked #155.

Optimize Financial first reported a position in KRYS in Q3 2025 and has held it in 3 quarters since. The position peaked at $704K in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Optimize Financial held 1,710 shares of Krystal Biotech worth $442K as of Q1 2026.
  • Optimize Financial sold 1,145 Krystal Biotech shares in Q1 2026, an estimated $305K.
  • Krystal Biotech made up 0.22% of Optimize Financial's portfolio in Q1 2026, its #155 holding.
  • Optimize Financial first reported a position in Krystal Biotech in Q3 2025 and has held it in 3 quarters since.
  • Optimize Financial's Krystal Biotech position peaked at $704K in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Optimize Financial's 13F filing for Q1 2026, filed 12 May 2026.